Quarterly ResultAug 5, 2026, 07:03 AM
AC Immune H1 2026 Net Loss CHF12.9M; Takeda Milestone $12M
AI Summary
AC Immune SA reported a significant reduction in its net loss for the first half of 2026, narrowing to CHF12.9 million from CHF40.2 million in the prior year. Total revenue surged to CHF16.2 million, driven by a $12 million milestone payment from Takeda and a CHF10 million upfront payment from Lilly. The company maintains a strong cash position of CHF75.4 million, expected to fund operations into Q4 2027, and anticipates further clinical results for its wholly-owned programs in H2 2026.
Key Highlights
- Net loss for H1 2026 significantly reduced to CHF12.9 million from CHF40.2 million in H1 2025.
- Total revenue for H1 2026 increased to CHF16.2 million from CHF2.3 million in H1 2025.
- Cash resources stood at CHF75.4 million as of June 30, 2026, providing funding into Q4 2027.
- Received a $12 million milestone payment from Takeda for initiating the AD4 cohort in the ABATE trial.
- Received a CHF10 million upfront payment from Lilly for the Morphomer-Tau small molecule program.
- R&D expenditures decreased to CHF22.2 million in H1 2026 from CHF32.7 million in H1 2025.
- Dr. Martin Zügel appointed interim CEO following Dr. Andrea Pfeifer's retirement.
Price Impact
More from ACIU